Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Sanjay Gupta
Based on 5 articles published since 2010
(Why 5 articles?)

Between 2010 and 2020, Sanjay Gupta wrote the following 5 articles about Melanoma.
+ Citations + Abstracts
1 Review Chemosaturation Percutaneous Hepatic Perfusion: A Systematic Review. 2017

Vogel, Arndt / Gupta, Sanjay / Zeile, Martin / von Haken, Rebecca / Brüning, Roland / Lotz, Gösta / Vahrmeijer, Alexander / Vogl, Thomas / Wacker, Frank. ·Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany. vogel.arndt@mh-hannover.de. · Department of Anaesthesiology, University Hospital Southampton, Tremona Road, Southampton, Hampshire, UK. · Department of Radiology and Neuroradiology, Asklepios Clinic Hamburg-Barmbek, Hamburg, Germany. · Department of Anaesthesiology, University Clinic Heidelberg, Heidelberg, Germany. · Department of Anaesthesiology, University Clinic Frankfurt, Frankfurt am Main, Germany. · Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands. · Institute of Diagnostic and Interventional Radiology, University Clinic Frankfurt, Frankfurt am Main, Germany. · Institute of Diagnostic and Interventional Radiology, Medizinische Hochschule Hannover, Hannover, Germany. ·Adv Ther · Pubmed #27798773.

ABSTRACT: The Hepatic CHEMOSAT FUNDING: Delcath Systems Inc., New York, NY, USA.

2 Clinical Trial Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. 2012

Davies, Michael A / Fox, Patricia S / Papadopoulos, Nicholas E / Bedikian, Agop Y / Hwu, Wen-Jen / Lazar, Alexander J / Prieto, Victor G / Culotta, Kirk S / Madden, Timothy L / Xu, Quanyun / Huang, Sha / Deng, Wanleng / Ng, Chaan S / Gupta, Sanjay / Liu, Wenbin / Dancey, Janet E / Wright, John J / Bassett, Roland L / Hwu, Patrick / Kim, Kevin B. ·Departments of Melanoma Medical Oncology, Systems Biology, Biostatistics, Pathology, Experimental Therapeutics, and Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. ·Clin Cancer Res · Pubmed #22223528.

ABSTRACT: PURPOSE: This phase I clinical trial was conducted to determine the safety, efficacy, and molecular effects of sorafenib with temsirolimus in patients with advanced melanoma. PATIENTS AND METHODS: Patients with stage IV or unresectable or recurrent stage III melanoma and Eastern Cooperative Oncology Group performance status of 0 to 1 were eligible. Sorafenib was given orally once or twice daily and temsirolimus was given i.v. weekly, both starting on day 1, with a 4-week cycle. Responses were assessed every 2 cycles per Response Evaluation Criteria in Solid Tumors criteria. Consenting patients with accessible tumors underwent optional tumor biopsies before treatment and after the second infusion of temsirolimus. Tumor biopsies were analyzed for activating mutations in BRAF and NRAS, and for expression of P-extracellular signal-regulated kinase (P-ERK) and P-S6 proteins. RESULTS: A total of 25 patients were accrued to the study. The maximum tolerated doses were sorafenib 400 mg every morning and 200 mg every evening and temsirolimus 25 mg i.v. weekly. Dose-limiting toxicities included thrombocytopenia, hand-foot syndrome, serum transaminase elevation, and hypertriglyceridemia. There were no complete or partial responses with the combination; 10 patients achieved stabilization of disease as their best response. The median progression-free survival was 2.1 months. Matching pretreatment and day 15 tumor biopsies showed marked inhibition of P-S6 with treatment in 3 of 4 evaluable patients, but minimal inhibition of P-ERK. CONCLUSIONS: Combination therapy with sorafenib and temsirolimus resulted in significant toxicity at higher dose levels, failed to achieve any clinical responses in genetically unselected patient population, and did not inhibit P-ERK.

3 Article Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer. 2019

Zhao, Jun / Wen, Xiaofei / Tian, Li / Li, Tingting / Xu, Chunyu / Wen, Xiaoxia / Melancon, Marites P / Gupta, Sanjay / Shen, Baozhong / Peng, Weiyi / Li, Chun. ·Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA. · Molecular Imaging Research Center of Harbin Medical University, Harbin, 150001, Heilongjiang, China. · Department of Interventional Radiology, Fourth Hospital of Harbin Medical University, Harbin, 150001, Heilongjiang, China. · Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. · Department of Biophysics, School of Life Science & Technology, University of Electronic Science and Technology of China, Chengdu, 610054, Sichuan, China. · Department of Melanoma Medical Oncology-Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA. · Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA. cli@mdanderson.org. ·Nat Commun · Pubmed #30796212.

ABSTRACT: Immunotherapy has only limited efficacy against pancreatic ductal adenocarcinoma (PDAC) due to the presence of an immunosuppressive tumor-associated stroma. Here, we demonstrate an effective modulation of that stroma by irreversible electroporation (IRE), a local ablation technique that has received regulatory approval in the United States. IRE induces immunogenic cell death, activates dendritic cells, and alleviates stroma-induced immunosuppression without depleting tumor-restraining collagen. The combination of IRE and anti-programmed cell death protein 1 (anti-PD1) immune checkpoint blockade promotes selective tumor infiltration by CD8

4 Article Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease. 2018

Karydis, Ioannis / Gangi, Alexandra / Wheater, Matthew J / Choi, Junsung / Wilson, Iain / Thomas, Kerry / Pearce, Neil / Takhar, Arjun / Gupta, Sanjay / Hardman, Danielle / Sileno, Sean / Stedman, Brian / Zager, Jonathan S / Ottensmeier, Christian. ·Cancer Sciences Academic Unit, University of Southampton, Southampton, United Kingdom. · University Hospital Southampton, Southampton, United Kingdom. · Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida. · Department of Radiology, Moffitt Cancer Center, Tampa, Florida. · Morsani School of Medicine, University of South Florida, Tampa, Florida. ·J Surg Oncol · Pubmed #29284076.

ABSTRACT: BACKGROUND: Metastatic uveal melanoma (UM) carries a poor prognosis; liver is the most frequent and often solitary site of recurrence. Available systemic treatments have not improved outcomes. Melphalan percutaneous hepatic perfusion (M-PHP) allows selective intrahepatic delivery of high dose cytotoxic chemotherapy. METHODS: Retrospective analysis of outcomes data of UM patients receiving M-PHP at two institutions was performed. Tumor response and toxicity were evaluated using RECIST 1.1 and Common Terminology Criteria for Adverse Events (CTCAE) v4.03, respectively. RESULTS: A total of 51 patients received 134 M-PHP procedures (median of 2 M-PHPs). 25 (49%) achieved a partial (N = 22, 43.1%) or complete hepatic response (N = 3, 5.9%). In 17 (33.3%) additional patients, the disease stabilized for at least 3 months, for a hepatic disease control rate of 82.4%. After median follow-up of 367 days, median overall progression free (PFS) and hepatic progression free survival (hPFS) was 8.1 and 9.1 months, respectively and median overall survival was 15.3 months. There were no treatment related fatalities. Non-hematologic grade 3-4 events were seen in 19 (37.5%) patients and were mainly coagulopathic (N = 8) and cardiovascular (N = 9). CONCLUSIONS: M-PHP results in durable intrahepatic disease control and can form the basis for an integrated multimodality treatment approach in appropriately selected UM patients.

5 Article Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma. 2011

Ahrar, Judy / Gupta, Sanjay / Ensor, Joe / Ahrar, Kamran / Madoff, David C / Wallace, Michael J / Murthy, Ravi / Tam, Alda / Hwu, Patrick / Bedikian, Agop Y. ·Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. ·Cancer Invest · Pubmed #21166498.

ABSTRACT: We reviewed the medical records of 42 patients with cutaneous melanoma metastatic to the liver who underwent hepatic artery chemoembolization (HACE) at our institution. HACE resulted in radiologic response (38.9%) or disease stabilization (47.2%) in most patients. The median overall survival (OS) and time to progression (TTP) of liver disease were 7.7 and 6 months, respectively. Patient's age, lactate dehydrogenase (LDH) levels, type of treatment, number of extrahepatic metastatic sites, and response to therapy were found to be significant predictors of OS after HACE. Prolonged survival was seen in patients who responded to HACE (p = .034).